Identification of serum amyloid a as a biomarker to distinguish prostate cancer patients with bone lesions

被引:85
作者
Le, L
Chi, K
Tyldesley, S
Flibotte, S
Diamond, DL
Kuzyk, MA
Sadar, MD
机构
[1] British Columbia Canc Agcy, Genom Sci Ctr, Vancouver, BC V5Z 4E6, Canada
[2] Ciphergen Biosyst Inc, Fremont, CA USA
关键词
D O I
10.1373/clinchem.2004.041087
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Prostate cancer has a propensity to metastasize to the bone. Currently, there are no curative treatments for this stage of the disease. Sensitive biomarkers that can be monitored in the blood to indicate the presence or development of bone metastases and/or response to therapies are lacking. Surf ace-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is an affinity-based approach that allows sensitive and high-throughput protein profiling and screening of biological samples. Methods: We used SELDI-TOF MS for protein profiling of sera from prostate cancer patients (n = 38) with and without bone metastases in our effort to identify individual or multiple serum markers that may be of added benefit to those in current use. Serum was applied to ProteinChip (R) surfaces (H4 and IMAC) to quickly screen samples and detect peaks predominating in the samples obtained from patients with bone metastases. Unique proteins in the bone metastasis cohort observed by SELDI-TOF MS were identified by two-dimensional gel electrophoresis, in-gel trypsin digestion, and tandem MS. The identities of the proteins were confirmed by ELISA and immunodepletion assays. Results: The cluster of unique proteins in the sera of patients with bone metastases was identified as isoforms of serum amyloid A. Machine-learning algorithms were also used to identify patients with bone metastases with a sensitivity and specificity of 89.5%. Conclusions: SELDI-TOF MS protein profiling in combination with other proteomic approaches may provide diagnostic tools with potential clinical applications and serve as tools to aid in the discovery of biomarkers associated with various diseases. (c) 2005 American Association for Clinical Chemistry.
引用
收藏
页码:695 / 707
页数:13
相关论文
共 61 条
[51]   Biological effect markers for exposure to carcinogenic compound and their relevance for risk assessment [J].
van Delft, JHM ;
Baan, RA ;
Roza, L .
CRITICAL REVIEWS IN TOXICOLOGY, 1998, 28 (05) :477-510
[52]   ANDROGEN RECEPTORS IN ENDOCRINE-THERAPY-RESISTANT HUMAN PROSTATE-CANCER [J].
VANDERKWAST, TH ;
SCHALKEN, J ;
DEWINTER, JAR ;
VANVROONHOVEN, CCJ ;
MULDER, E ;
BOERSMA, W ;
TRAPMAN, J .
INTERNATIONAL JOURNAL OF CANCER, 1991, 48 (02) :189-193
[53]   Pan-cadherin as a high level phenotypic biomarker for prostate cancer [J].
Wehbi, NK ;
Dugger, AL ;
Bonner, RB ;
Pitha, JV ;
Hurst, RE ;
Hemstreet, GP .
JOURNAL OF UROLOGY, 2002, 167 (05) :2215-2221
[54]  
WEINSTEIN PS, 1984, SCAND J IMMUNOL, V19, P193
[55]   Witten IH, Frank E: Data Mining: Practical Machine Learning Tools and Techniques 2nd editionSan Francisco: Morgan Kaufmann Publishers; 2005:560. ISBN 0-12-088407-0, £34.99 [J].
Francisco Azuaje .
BioMedical Engineering OnLine, 5 (1)
[56]   Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate [J].
Wolff, JM ;
Ittel, T ;
Borchers, H ;
Brauers, A ;
Jakse, G .
UROLOGIA INTERNATIONALIS, 1998, 61 (01) :12-16
[57]   Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry:: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures [J].
Wright, GL ;
Cazares, LH ;
Leung, SM ;
Nasim, S ;
Adam, BL ;
Yip, TT ;
Schellhammer, PF ;
Gong, L ;
Vlahou, A .
PROSTATE CANCER AND PROSTATIC DISEASES, 1999, 2 (5-6) :264-276
[58]   Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay [J].
Xiao, Z ;
Jiang, X ;
Beckett, ML ;
Wright, GL .
PROTEIN EXPRESSION AND PURIFICATION, 2000, 19 (01) :12-21
[59]  
Zhau Haiyen E., 2000, Cancer, V88, P2995, DOI 10.1002/1097-0142(20000615)88:12+<2995::AID-CNCR15>3.3.CO
[60]  
2-P